Business Description
Oncoinvent ASA
ISIN : NO0010779341
Description
Oncoinvent ASA is a clinical-stage company focused on developing radiopharmaceutical drugs against cancer. Its product candidate Radspherin is designed for targeted local treatment of metastatic cancers in body cavities using potent alpha radiation. It is currently evaluated in a Phase 2 randomized controlled study of ovarian cancer, building on previous encouraging safety data and signals of efficacy.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.94 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 0.64 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.5 | |||||
| Quick Ratio | 0.5 | |||||
| Cash Ratio | 0.24 | |||||
| Days Payable | 251.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 4810.05 | |||||
| Operating Margin % | 17083.25 | |||||
| Net Margin % | 16104.31 | |||||
| FCF Margin % | 16628.47 | |||||
| ROE % | -199.14 | |||||
| ROA % | -91.42 | |||||
| ROIC % | -156.42 | |||||
| ROC (Joel Greenblatt) % | -183.92 | |||||
| ROCE % | -168.4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 21.9 | |||||
| Price-to-Tangible-Book | 21.43 | |||||
| EV-to-EBIT | -4.1 | |||||
| EV-to-EBITDA | -4.49 | |||||
| EV-to-Revenue | -663.16 | |||||
| EV-to-FCF | -3.99 | |||||
| Earnings Yield (Greenblatt) % | -24.39 | |||||
| FCF Yield % | -25.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncoinvent ASA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | -0.418 | ||
| EPS (TTM) (kr) | -2.536 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 0 | ||
| 20-Day SMA (kr) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 2.5 - 4 | ||
| Shares Outstanding (Mil) | 92.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncoinvent ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncoinvent ASA Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oncoinvent ASA Frequently Asked Questions
What is Oncoinvent ASA(OSL:ONCIN)'s stock price today?
The current price of OSL:ONCIN is kr3.00. The 52 week high of OSL:ONCIN is kr4.00 and 52 week low is kr2.50.
When is next earnings date of Oncoinvent ASA(OSL:ONCIN)?
The next earnings date of Oncoinvent ASA(OSL:ONCIN) is 2025-02-27.
Does Oncoinvent ASA(OSL:ONCIN) pay dividends? If so, how much?
Oncoinvent ASA(OSL:ONCIN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers